ATE331703T1 - Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln - Google Patents
Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormittelnInfo
- Publication number
- ATE331703T1 ATE331703T1 AT01926512T AT01926512T ATE331703T1 AT E331703 T1 ATE331703 T1 AT E331703T1 AT 01926512 T AT01926512 T AT 01926512T AT 01926512 T AT01926512 T AT 01926512T AT E331703 T1 ATE331703 T1 AT E331703T1
- Authority
- AT
- Austria
- Prior art keywords
- antitumor agents
- treating tumors
- retinoid compounds
- compounds along
- rar alpha
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- -1 RETINOID COMPOUNDS Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101001100204 Homo sapiens Ras-related protein Rab-40A-like Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100038416 Ras-related protein Rab-40A-like Human genes 0.000 abstract 1
- 101100236975 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL11 gene Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54214800A | 2000-04-04 | 2000-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE331703T1 true ATE331703T1 (de) | 2006-07-15 |
Family
ID=24162539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01926512T ATE331703T1 (de) | 2000-04-04 | 2001-04-02 | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6387950B2 (enExample) |
| EP (2) | EP1268405B1 (enExample) |
| JP (1) | JP2003534246A (enExample) |
| AT (1) | ATE331703T1 (enExample) |
| AU (1) | AU2001253045A1 (enExample) |
| CA (1) | CA2405136C (enExample) |
| DE (1) | DE60121145T2 (enExample) |
| ES (1) | ES2267754T3 (enExample) |
| TW (1) | TWI281911B (enExample) |
| WO (1) | WO2001074759A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903121B1 (en) * | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| EP1935869A1 (en) * | 2000-10-02 | 2008-06-25 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
| WO2002028810A2 (en) * | 2000-10-02 | 2002-04-11 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
| US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
| WO2005093426A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) |
| LT1937244T (lt) | 2005-09-30 | 2018-11-12 | Io Therapeutics, Llc | Vėžio gydymas specifiniais rxr agonistais |
| EP2685972A4 (en) * | 2011-03-14 | 2014-08-13 | Io Therapeutics Inc | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| EP3277272B1 (en) | 2015-03-31 | 2021-08-04 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-agonists |
| KR102149321B1 (ko) | 2015-10-31 | 2020-08-28 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
| WO2017091762A1 (en) | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
| KR102549273B1 (ko) | 2016-03-10 | 2023-06-28 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| NZ745704A (en) | 2016-03-10 | 2019-04-26 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| KR20240157122A (ko) | 2016-04-08 | 2024-10-31 | 사이로스 파마수티컬스, 인크. | Aml 및 mds 치료용 rara 효능제 |
| CA3069672A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
| EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| EP4444287A4 (en) | 2021-12-07 | 2025-05-28 | Io Therapeutics, Inc. | USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER |
| KR20240115316A (ko) | 2021-12-07 | 2024-07-25 | 아이오 테라퓨틱스, 인크. | 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도 |
| CN114703227B (zh) * | 2022-01-27 | 2023-11-10 | 中国科学院生态环境研究中心 | 基于MCF-7细胞系构建的RARα效应物体外筛选方法 |
| CN119451672A (zh) | 2022-06-27 | 2025-02-14 | Io治疗公司 | 四氢萘酚的合成及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE617614T1 (de) * | 1991-12-18 | 1995-06-08 | Baylor College Of Medicine, Houston, Tex. | Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen. |
| US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
-
2001
- 2001-03-30 TW TW090107695A patent/TWI281911B/zh not_active IP Right Cessation
- 2001-04-02 JP JP2001572454A patent/JP2003534246A/ja active Pending
- 2001-04-02 AT AT01926512T patent/ATE331703T1/de not_active IP Right Cessation
- 2001-04-02 DE DE60121145T patent/DE60121145T2/de not_active Expired - Lifetime
- 2001-04-02 EP EP01926512A patent/EP1268405B1/en not_active Expired - Lifetime
- 2001-04-02 US US09/824,111 patent/US6387950B2/en not_active Expired - Fee Related
- 2001-04-02 WO PCT/US2001/010410 patent/WO2001074759A1/en not_active Ceased
- 2001-04-02 EP EP05025970A patent/EP1650188A1/en not_active Withdrawn
- 2001-04-02 ES ES01926512T patent/ES2267754T3/es not_active Expired - Lifetime
- 2001-04-02 AU AU2001253045A patent/AU2001253045A1/en not_active Abandoned
- 2001-04-02 CA CA002405136A patent/CA2405136C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2405136A1 (en) | 2001-10-11 |
| WO2001074759A1 (en) | 2001-10-11 |
| US20010039293A1 (en) | 2001-11-08 |
| AU2001253045A1 (en) | 2001-10-15 |
| EP1268405A1 (en) | 2003-01-02 |
| TWI281911B (en) | 2007-06-01 |
| ES2267754T3 (es) | 2007-03-16 |
| US6387950B2 (en) | 2002-05-14 |
| EP1268405B1 (en) | 2006-06-28 |
| JP2003534246A (ja) | 2003-11-18 |
| CA2405136C (en) | 2009-06-16 |
| DE60121145D1 (de) | 2006-08-10 |
| EP1650188A1 (en) | 2006-04-26 |
| DE60121145T2 (de) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121145D1 (de) | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| FI935306L (fi) | Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana | |
| DE60016393D1 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
| JP2003522724A5 (enExample) | ||
| KR900015729A (ko) | 흥분성 아미노산 길항제 | |
| DK0694545T3 (da) | Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder | |
| EA199901075A1 (ru) | Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста | |
| ATE187642T1 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
| KR880009948A (ko) | 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 | |
| NO923199D0 (no) | Terapeutiske forbindelser | |
| RU94037233A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований | |
| RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
| FI923664A0 (fi) | Piperidinderivat. | |
| NO20014240D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| NO923198D0 (no) | Terapeutiske midler | |
| KR927002224A (ko) | 항종양효과증강제 및 항종양제 | |
| RU2001118219A (ru) | Ингибитор ангиогенеза | |
| KR920019767A (ko) | 티아졸 유도체 | |
| ES2049703T1 (es) | Derivados de acidos biliares sulfurados. | |
| PT985414E (pt) | Metodo de tratamento de glaucoma e retinopatia isquemica | |
| KR950703528A (ko) | 프로스타글란딘 e₁유연체 | |
| ATE324118T1 (de) | Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |